AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2003 JAN 1 - (NewsRx.com & NewsRx.net) -- According to a study from the United States, "Group B streptococci (GBS) are among the most common causes of life-threatening neonatal infections. Vaccine development since the late 1970s has focused on the capsular polysaccharides, but a safe, effective product is still not available."
Q. Cheng and colleagues, University of Minnesota, said their "quest for a vaccine turned to the streptococcal C5a peptidase (SCPB). This surface protein is antigenically conserved across most if not all serotypes," they noted.
They used a mouse model "to assess the impact of SCPB on clearance of GBS from the lungs of intranasally infected animals."
The researchers reported that "[m]utational inactivation of SCPB resulted in more-rapid clearance of streptococci from the lung."
"Immunization with recombinant SCPB alone or SCPB conjugated to type III capsular polysaccharide produced serotype-independent protection, which was evidenced by more-rapid clearance of the serotype VI strain from the lungs," they wrote.
"Immunization of mice with tetanus toxoid-type III polysaccharide conjugate did not produce protection, confirming that protection induced by SCPB conjugates was independent of type III polysaccharide antigen. Histological ...
Source: HighBeam Research, C5a peptidase enhances clearance of group B Strep from lungs of...